The Executive Scientific Committee of the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress 2013 has awarded Efstathios Zikos and Divine Ediebah of the EORTC Quality of Life Department Fellowship Grants to attend the European Cancer Congress 2013 which will be held in Amsterdam from 27 September to 1 October 2013.
Divine will present a poster, "Patient-proxy agreement of health-related quality of life (HRQOL) measurements in low-grade glioma patients" (Abstract Id: E17-2609), during the "Symptom Science" poster session scheduled on Monday, September 30, 2013 from 09:30 to 12:00 o'clock. In this same session Efstathios will present, "Health-related quality of life in small-cell lung cancer: A systematic review on reporting of methodological and clinical issues in randomized controlled trials" (Abstract Id: E17-2527). Efstathios' abstract will also be discussed in a Poster Discussion Session.
The two quality of life researchers will also present research results at the 20th Annual Conference of the International Society for Quality of Life Researchers (ISOQOL) to be held 9-12 October 2013 in Miami, Florida. Efstathios Zikos will present "A Review of Health-Related Quality of Life Assessment in
EORTC Cancer Clinical Trials" (Presentation Number: 1090), and Divine Ediebah will present "Patient-proxy agreement of health-related quality of life (HRQOL) measurements in low-grade glioma patients" (Presentation Number: 1093). For his presentation at ISOQOL, Divine was chosen by the Scholarship Selection Committee to receive one of this year's Developing Country Scholarships.
These research projects were supported by the EORTC Charitable Trust, La Fondation Contre le Cancer, and Patient Reported Outcome and Behavioral Evidence (PROBE).
Divine E. Ediebah has been a Fellow Biostatistician in the Quality of Life Department at EORTC Headquarters since March 2011. He is involved biostatistical analyses on clinical trials data in the Patient Reported Outcome and Behavioral Evidence (PROBE) projects and works in collaboration with the various EORTC disease oriented groups. He holds Masters Degrees in Applied Statistics and Biostatistics from Hasselt University and worked previously as a consultant in Biostatistics with GlaxoSmithKline Biological's 4Clinics for clinical studies for Flu, Malaria and Herpes Zoster vaccines. His research interests include methods in the analyses of Quality of Life data from clinical trials, longitudinal data, survival data, multivariate data and categorical data analysis and joint modeling. He is currently pursuing his PhD at the VU Medical Center of Amsterdam (joint modeling of HRQOL outcome and other biomarkers such as overall survival, progression-free survival, MMSE, genetic biomarkers, etc).
Efstathios Zikos is Quality of Life Research Manager/Scientific Coordinator in the EORTC Headquarters Quality of Life Department since March 2011. He leads the daily supervision of the PROBE team and is responsible for major research studies from conception to publication and the coordination of the advisory board of PROBE. He received his BSc in Psychology from Anglia Ruskin University, Cambridge, his MSc in Social and Organizational Psychology from Leiden University, and his interdisciplinary MA in Society, Science and Technology from Maastricht University. He completed his specialty in Management and Economics of Innovation, at the Autonomous University of Madrid, and his practical training in clinical psychopathology and neuropsychological assessment at the 1st Psychiatric Department of Athens University Medical School. He attained his certification as a Licensed Psychologist from the Greek Authorities and has worked as a Science and Technology Consultant and volunteer psychologist to vulnerable groups of patients, refugees and children for the Red Cross, the Médecins sans Frontières and the Arc of the World. He is currently pursuing his PhD in the Academic Medical Center of the University of Amsterdam (Methodological challenges in HRQOL research and analysis of patient-reported outcomes data in EORTC cancer clinical trials).